Prophylactic Antimicrobials for Prevention of Febrile Neutropenia in Tumour‐Bearing Dogs Treated With Lomustine
Veterinary and Comparative Oncology · 2025
DOI: 10.1111/vco.13022 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Veterinary and Comparative Oncology, 2025. Verfasst von Meredith Gumash und 3 weiteren Autor:innen. Beteiligte Einrichtung: Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA. Hauptthemen laut MEDLINE: Dog Diseases, Lomustine, Antineoplastic Agents, Alkylating, Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.
Abstract (Originalsprache)
CCNU (1‐[2‐chloroethyl]‐3‐cyclohexyl‐1‐nitrosurea), lomustine, is an oral alkylating agent in the nitrosourea subgroup. The dose‐limiting toxicity of CCNU is neutropenia most frequently documented 7 days after its administration. Use of prophylactic antimicrobials to prevent chemotherapy‐related febrile neutropenia (FN) and its associated morbidity and mortality has been well‐documented in human oncology, but this information is limited in the veterinary literature. The purpose of this multi‐institutional retrospective study was to assess whether antimicrobial prophylaxis reduced the risk of FN approximately 7 days after CCNU administration in tumour‐bearing dogs. A secondary goal was to identify risk factors for fever development in neutropenic dogs. Two hundred dogs were included in the study. One hundred and fifty‐three dogs (76.5%) were neutropenic at the first post‐CCNU recheck. One hundred and six (69.3%) dogs received prophylactic antimicrobials and 47 (30.7%) did not. Of the 106 dogs on prophylactic antimicrobials, 8 (7.5%) developed FN. Of the 47 dogs in the no‐prophylactic antimicrobials group, 4 (8.5%) developed FN. Use of prophylactic antimicrobials did not reduce the risk of development of FN ( p = 0.84). Older age (> 9 y), lower weight and body surface area, and pre‐treatment with chemotherapy or radiation therapy were significantly associated with development of FN ( p = 0.009, p = 0.023, p = 0.015 and p = 0.01). Patients with a lower absolute neutrophil count, and a higher VCOG‐CTCAE v2 neutropenia grade were also at an increased risk of developing FN ( p = 0.01, p < 0.001). Additional studies may help establish guidelines for antimicrobial prophylaxis in dogs treated with CCNU, especially for those at high‐risk for FN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Tennessee, USA.
- Bailey Small Animal Teaching Hospital, Auburn University, Auburn, Alabama, USA.
Zitieren
APA
Gumash, M., Martin, O. A., Lindley, S. E. S., & Zhu, X. (2025). Prophylactic Antimicrobials for Prevention of Febrile Neutropenia in Tumour‐Bearing Dogs Treated With Lomustine. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.13022
Vancouver
Gumash M, Martin OA, Lindley SES, Zhu X. Prophylactic Antimicrobials for Prevention of Febrile Neutropenia in Tumour‐Bearing Dogs Treated With Lomustine. Veterinary and Comparative Oncology. 2025. doi:10.1111/vco.13022
BibTeX
@article{Gumash2025,
author = {Gumash, Meredith and Martin, Olya A and Lindley, Stephanie E S and Zhu, Xiaojuan},
title = {Prophylactic Antimicrobials for Prevention of Febrile Neutropenia in Tumour‐Bearing Dogs Treated With Lomustine},
journal = {Veterinary and Comparative Oncology},
year = {2025},
doi = {10.1111/vco.13022}
}
EUVIMED